Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Stock Recap #PipelineProspector
1. Sndx-5613
2. 2169919-21-3
3. Lz0m43nnf2
4. Sndx5613
5. Sndx-5613 Free Base
6. N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-n-propan-2-ylbenzamide
7. Sndx50613
8. Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-
9. Sndx-50613
10. Revumenib [inn]
11. Unii-lz0m43nnf2
12. Sndx5613 Free Base
13. Sndx50613 Free Base
14. Chembl4650827
15. Schembl19693219
16. Schembl19693428
17. Gtpl11882
18. Sndx-50613 Free Base
19. Ex-a4343
20. Nsc825775
21. S8996
22. Nsc-825775
23. Ac-36885
24. Hy-136175
25. Cs-0120274
26. N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-n-isopropylbenzamide
| Molecular Weight | 630.8 g/mol |
|---|---|
| Molecular Formula | C32H47FN6O4S |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Exact Mass | 630.33635334 g/mol |
| Monoisotopic Mass | 630.33635334 g/mol |
| Topological Polar Surface Area | 116 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 1040 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
WEEKLY NEWS RECAP #Phispers
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
86
PharmaCompass offers a list of Revumenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Revumenib manufacturer or Revumenib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Revumenib manufacturer or Revumenib supplier.
A Revumenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Revumenib, including repackagers and relabelers. The FDA regulates Revumenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Revumenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Revumenib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Revumenib supplier is an individual or a company that provides Revumenib active pharmaceutical ingredient (API) or Revumenib finished formulations upon request. The Revumenib suppliers may include Revumenib API manufacturers, exporters, distributors and traders.
click here to find a list of Revumenib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
Revumenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Revumenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Revumenib GMP manufacturer or Revumenib GMP API supplier for your needs.
A Revumenib CoA (Certificate of Analysis) is a formal document that attests to Revumenib's compliance with Revumenib specifications and serves as a tool for batch-level quality control.
Revumenib CoA mostly includes findings from lab analyses of a specific batch. For each Revumenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Revumenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Revumenib EP), Revumenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Revumenib USP).
